Posted by Michael Wonder on 30 Nov 2017
Advancing medicinal nicotine replacement therapies as new drugs – a new step in FDA’s comprehensive approach to tobacco and nicotine
29 November 2017 - As the leading cause of preventable disease and death in the United States, tobacco causes more than 480,000 deaths every year.
To address this devastation, earlier this year FDA announced a new regulatory plan to lower this burden of tobacco-related disease and death. The plan takes a comprehensive approach to nicotine and tobacco, including an initiative to lower nicotine in cigarettes to minimally addictive or non-addictive levels. Aimed at shifting the trajectory of tobacco-related disease and death, the agency’s approach recognises that nicotine is delivered through products posing a continuum of risk.
This ranges from combusted cigarettes at one end, to nicotine replacement therapy products – designed to safely reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking – at the other.
